[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604087":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":39,"centralContacts":48,"locations":27,"responsibleParty":59,"collaborators":27,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":27,"enrollmentInfo":71,"targetDuration":27,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":89,"whyStopped":27,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":27},{"fullName":5,"class":6},"Centre Hospitalier St Anne","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Cilostazol + Nimodipine","EXPERIMENTAL","In the cilostazol arm, patients will receive standard care for aneurysmal subarachnoid hemorrhage, including nimodipine administration as recommended by French and European guidelines for delayed cerebral ischemia (DCI) prevention. In addition, participants will receive cilostazol 100 mg twice daily, administered orally or via gastric tube if swallowing is not possible, for 14 consecutive days, starting within 96 hours of hemorrhage onset. Cilostazol tablets may be crushed for enteral administration. All other preventive and curative treatments for vasospasm or DCI-such as hypertensive therapy, milrinone, or endovascular interventions-are permitted at the discretion of the treating physician. Monitoring will include clinical status, occurrence of vasospasm, DCI, cerebral infarction, and cilostazol-related adverse events. Follow-up visits and safety assessments will be identical to the placebo arm.",[13,14],"Biological: Cilostazol (Pletal®) 100 mg Tablets","Drug: Nimodipine group",{"label":16,"type":17,"description":18,"interventionNames":19},"Nimodipine + Placebo","PLACEBO_COMPARATOR","In the placebo arm, patients will receive standard care for aneurysmal subarachnoid hemorrhage, which must include nimodipine for the prevention of delayed cerebral ischemia (DCI) as per French and European guidelines. Nimodipine will be administered orally\u002Fenterally or intravenously, with dose, route, and duration decided by the treating physician according to patient status and local practice. Participants will receive a placebo, visually identical to cilostazol tablets, given orally or via gastric tube twice daily for 14 days, starting within 96 hours of hemorrhage onset. All other preventive or curative treatments for vasospasm or DCI-such as hypertensive therapy, milrinone, or endovascular procedures-are allowed at the physician's discretion. Monitoring, follow-up, and safety assessments will be performed in the same manner as in the experimental arm.",[20,14],"Drug: Placebo",[22,28,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"BIOLOGICAL","Cilostazol (Pletal®) 100 mg Tablets","100 mg orally or via feeding tube twice daily for 14 days, starting within 96 hours after aneurysmal subarachnoid hemorrhage onset. Tablets may be crushed for enteral administration.",[9],null,{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Placebo","Oral or enteral placebo, visually identical to cilostazol, twice daily for 14 days, starting within 96 hours after hemorrhage onset.",[16],[34],"Placebo (matching Cilostazol)",{"type":29,"name":36,"description":37,"armGroupLabels":38,"otherNames":27},"Nimodipine group","Administered orally, enterally, or intravenously for 21 days as part of standard of care. Dose, route, and duration determined by treating physician according to clinical condition and guidelines.",[9,16],[40,44],{"name":41,"affiliation":42,"role":43},"Caroline SCHIMPF, Doctor","Chef de service Anesthésie - Réanimation GHU Paris - Neuro Sainte-Anne","STUDY_CHAIR",{"name":45,"affiliation":46,"role":47},"Aurélien MAZERAUD, DOCTOR","Anesthésie - Réanimation GHU Paris - Neuro Sainte-Anne","PRINCIPAL_INVESTIGATOR",[49,55],{"name":50,"role":51,"phone":52,"phoneExt":53,"email":54},"Khaoussou SYLLA, DR","CONTACT","01.45.65.76.78","+33","K.SYLLA@ghu-paris.fr",{"name":56,"role":51,"phone":57,"phoneExt":53,"email":58},"OUIZA MANSEUR, Project manager","01 45 65 84 86","ouiza.manseur@ghu-paris.fr",{"type":60,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100604087","phase-3-cilostazol-with-nimodipine-to-improve-outcome-after-aneurysmal-subarachnoid-hemorrhage-100604087",false,"NCT07144956","Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage","Is Adding Cilostazol to Nimodipine Improving Neurological Outcome of Patients With Aneurysmal Subarachnoid Hemorrhage? A Randomized, Double Blind, Placebo-controlled Trial","CASH","Inclusion Criteria:\n\n* Adult patients admitted to an ICU with SAH related to a ruptured cerebral aneurysm occurring within the last 96 hours.\n* Aneurysm successfully secured by surgical clipping or endovascular coiling\n* Consent of the patient or, if not possible, from a proxy (emergency clause).\n* Registration in a national health care system\n\nExclusion Criteria:\n\n* \\- Precritical modified Rankin Scale (mRS) \\> 2\n* Nonaneurysmal SAH\n* Delayed \\>96h admission after first symptoms of SAH\n* Coma defined by GCS of 3-5 with untreatable aneurysm will be excluded\"\n* Known allergy to cilostazol\n* Pregnancy\n* Pre-existing major hepatic, renal, pulmonary or cardiac disease\n* Concomitant use of one other anti-platelet and\u002For anticoagulant agent\n* SAH diagnosed on Lumbar puncture with no evidence of blood on CT.\n* Tutelage or guardianship","ALL","18 Years",{"count":72,"type":73},630,"ESTIMATED","INTERVENTIONAL",[76],"PHASE3","The CASH study is a randomized, double-blind, placebo-controlled trial evaluating whether adding cilostazol to standard nimodipine therapy improves neurological outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). The primary objective is to assess functional outcome at 6 months using the modified Rankin Scale. A total of 630 patients will be enrolled within 96 hours of aSAH onset and treated for 14 days. The study is conducted across 9 centers in France, funded by a PHRC, and overseen by an independent monitoring board.",[79],"Aneurysmal Subarachnoid Hemorrhage",[81,82,83,84,85,86,87,88],"Cilostazol","Nimodipine","Vasospasm","Modified Rankin Scale (mRS)","Neurological outcome","Double-blind","Randomized Controlled Trial","Multicenter clinical trial","NOT_YET_RECRUITING","2025-09-04",{"date":92,"type":93},"2025-09-10","ACTUAL",{"date":95,"type":73},"2025-12-15",{"date":97,"type":73},"2029-12-14",{"name":5,"class":6}]